New research suggests Trudhesa is more likely to compete with Biohaven’s Nurtec ODT, AbbVie’s Ubrelvy, and Eli Lilly’s Reyvow over...
Approaching one year on the market to treat lupus nephritis, comprehensive launch coverage reveals a widening gap in attitudes and...
Another year of missed opportunity will pass by while other pipeline agents launch, uptake of BMS’ Zeposia potentially picks up,...
450 US specialists provided feedback on their use and perceptions of biosimilar agents and their impact on the total treatment...
Implications abound for historic leader Amgen and newer companies with paradigm-shifting SGLT2 inhibitors (AstraZeneca [Farxiga], Vifor/Janssen [Invokana], Eli Lilly/Boehringer Ingelheim...
The negative CDEC reimbursement recommendation for BMS’ Zeposia highlights the risk (or opportunity) for Janssen’s Ponvory launch, while the advent...
As brand satisfaction and patient candidacy numbers continue to erode, Spherix will assess the impact of the recent patient death...
Recent survey of 255 nephrologists in clinical practice in France, Germany, Italy, Spain, and the UK reveals EVRENZO offers the...
A high percentage of undiagnosed patients and difficulties with treatment adherence among this mostly younger male patient population could be...
The new addition ties Spherix’s unique approach to syndicated research to a highly dynamic market, filling the white space for...
New patient-level data show that newer market entrants, such as BMS’ Zeposia and Novartis’ Kesimpta, are gaining traction in the...
New launch tracking reports and patient audit data show early excitement and ample opportunity for the latest approvals as well...
